Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.45 |
| ▸ | MET | P08581 | 15/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | MST1R | Q04912 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | YES1 | P07947 | 1/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | LTK | P29376 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110077 | 1.00 | ABL1 (0.45) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3099475 | 0.95 | ABL1 (0.47) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3097959 | 0.93 | MET (0.43) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3104496 | 0.93 | MET (0.43) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3098297 | 0.93 | MET (0.43) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3102583 | 0.92 | MET (0.42) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3650561 | 0.92 | MET (0.42) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3102160 | 0.92 | MET (0.42) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3104591 | 0.92 | MET (0.42) | ABL1METKDRFGFR2AXL | |
| SCHEMBL3102528 | 0.92 | MET (0.42) | ABL1METKDRFGFR2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188078-B2 | 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | claimed |
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | US | claimed |
| US-8188078-B2 | 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | MET, ALK, JAK2 | ABL1 4/4885MET 1/4885KDR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.